Lyell Immunopharma (LYEL) Price/OCF Ratio: History & Chart

Lyell Immunopharma, Inc.(LYEL)

Biotechnology · South San Francisco, CA

$8.94-0.13 (-1.43%)

Delayed quote: Oct 6, 2026, 12:45 PM EDT

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

South San Francisco, CA

161 employees

www.lyell.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lynn Seely

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Lyell Immunopharma, Inc. (LYEL)	$219.07M	N/A	N/A	N/A	N/A
Anbio Biotechnology Class A Ordinary Shares (NNNN)vs ›	$217.26M	N/A	N/A	N/A	N/A
Keros Therapeutics, Inc. (KROS)vs ›	$221.87M	N/A	9.04	9.10	9.10
Niagen Bioscience Inc (NAGE)vs ›	$214.64M	36.08	45.91	60.75	60.42
Alector, Inc. (ALEC)vs ›	$213.72M	N/A	3.18	3.20	4.43
Prelude Therapeutics Incorporated (PRLD)vs ›	$213.50M	N/A	N/A	N/A	N/A
Profound Medical Corp. (PROF)vs ›	$226.56M	N/A	N/A	N/A	N/A
Compugen Ltd. (CGEN)vs ›	$211.33M	N/A	N/A	N/A	N/A
Cartesian Therapeutics, Inc. (RNAC)vs ›	$208.60M	N/A	10.01	10.01	10.01
Sionna Therapeutics, Inc. (SION)vs ›	$208.36M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Lyell Immunopharma, Inc. (LYEL)

$219.07M

N/A

Anbio Biotechnology Class A Ordinary Shares (NNNN)vs ›

$217.26M

N/A

Keros Therapeutics, Inc. (KROS)vs ›

$221.87M

N/A

9.04

9.10

Niagen Bioscience Inc (NAGE)vs ›

$214.64M

36.08

45.91

60.75

60.42

Alector, Inc. (ALEC)vs ›

$213.72M

N/A

3.18

3.20

4.43

Prelude Therapeutics Incorporated (PRLD)vs ›

$213.50M

N/A

Profound Medical Corp. (PROF)vs ›

$226.56M

N/A

Compugen Ltd. (CGEN)vs ›

$211.33M

N/A

Cartesian Therapeutics, Inc. (RNAC)vs ›

$208.60M

N/A

10.01

Sionna Therapeutics, Inc. (SION)vs ›

$208.36M

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

LYEL Price/OCF Ratio Metrics

LYEL Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics